Translation Control Therapeutics
Lighting up a novel target space
New approach
New technology
New drugs

AnimaBiotech

Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that control mRNA translation

mRNA translation modulators -
a novel target space

mRNA Translation
Ribosome accessory proteins
Epitranscriptomics (mRNA modifying proteins)
Splicing factors
Modifiers of ribosomal proteins (Kinases, methylases etc...)
tRNA abundance
RNA binding proteins

Tremendous opportunities - unique advantages

Tissue selective drugs
Specifically decrease or increase
protein translation
Chemically diverse hits against
novel target space
New insight into disease biology

Our Approach

Our platform identifies small molecules that selectively modulate the mRNA translation of target proteins. The novel target space enables the discovery of drugs that can either decrease or increase the production of proteins in a tissue selective manner.

Play Video

Specifically decrease or increase the mRNA translation of target proteins

See the Light of Protein Translation

Tissue Selectivity

Tissues use different regulatory proteins for the same mRNA allowing for selective Translation Control

Product Pipeline

Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors), Huntington’s Disease (monitoring mutant Huntingtin translation pausing) and Repeat Associated Diseases (translation malfunctions).

Program
DISCOVERY
OPTIMIZATION
IND ENABLING
Collagen I - Target2 Liver Fibrosis
RSV Viral Translation Inhibitors
C-Myc Oncology / Longevity
Huntingtin Huntington's disease
Repeat Associated Diseases Translation malfunctions

Pharma Collaborations

Anima Biotech announces an exclusive collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets

$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.

For partnering inquiries, please contact [email protected].

17 Scientific Collaborations

14 Publications

Coverage

News & Events

  • 2nd Annual RNA as a Drug Target Conference

    When: Sep. 16th, 2020 - Sep. 18th, 2020

    Anima Biotech has been invited to present and participate on an expert panel during the Cambridge Healthtech Institute’s 2nd Annual RNA as a Drug Target Conference, between Sep. 16-17, 2020. Yochi Slonim, Co-founder and CEO of Anima Biotech, will be giving a presentation during the RNA as a Drug Target session, titled, “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators, on Thursday, Sep. 17 at 10:15 a.m. ET. As part of the same session, Dr. Iris Alroy, VP of R&D, will participate on an expert wrap-up panel discussion on Thursday, Sep. 17 at 11:35 a.m. ET.

    Download Press Release »

    Visit the conference website »

  • Cambridge Healthtech Institute’s Inaugural RNA as a Small Molecule Target Symposium

    When: Aug. 28th, 2020

    Anima Biotech has been invited to give an overview of its Translation Control Therapeutics platform at the Inaugural RNA as a Small Molecule Target Symposium. Co-founder and CEO, Yochi Slonim and vice president of research and development Dr. Iris Alroy will jointly present a talk titled “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators,” on Friday, Aug.

    Download Press Release »

    Visit the conference website »

  • ChinaBio Partnering Forum

    When: Aug. 25th, 2020 - Aug. 27th, 2020

    Anima Biotech’s co-founder and CEO, Yochi Slonim, has been invited to present about its business, technology and partnering strategies during the ChinaBio Partnering Forum 2020.

    The ChinaBio Partnering Forum is the premier life science partnering event in China. The event attracts biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.

    Download Press Release »

    Visit the conference website »